search
Back to results

EASH Dressing on Chronic Venous Leg Ulcers

Primary Purpose

Leg Ulcer

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
EASH dressing
Sponsored by
ConvaTec Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leg Ulcer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects over 18 years, willing and able to provide written informed consent.
  • Subjects who have an ankle to brachial pressure index (ABPI) of 0.8 or greater
  • Subjects who have a venous leg ulcer (i.e. CEAP classification of C6 1), with duration less than 24 months and size ranging between 5 cm2-40 cm2.
  • Subjects' leg ulcers will meet at least 3 of the 5 following clinical signs of infection: pain between two dressing changes, peri-ulcer skin erythema/inflammation, oedema, malodour (foul odour), and heavy exudate.
  • Subjects who agree to wear compression therapy daily in combination with the trial dressing.

Exclusion Criteria:

  • Subjects with a history of skin sensitivity to any of the components of the study product.
  • Subjects who have had current local or systemic antibiotics in the week prior to inclusion with the exception of wounds that are considered to be clinically infected at baseline.
  • Subjects whose leg ulcers are malignant, or who have had recent deep venous thrombosis or venous surgery within the last 3 months.
  • Subjects who have progressive neoplastic lesion treated by radiotherapy or chemotherapy, or on-going treatment with immunosuppressive agents
  • Subjects exhibiting any other medical condition which, according to the Investigator, justifies the subject's exclusion from the study
  • Subjects who have participated in a clinical study within the past month.

Sites / Locations

  • Mikomed
  • Cross Medica
  • Medservice
  • Wound Healing Research Unit
  • Axbridge & Wedmore Medical Practice
  • Arrowe Park Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

EASH

Arm Description

Outcomes

Primary Outcome Measures

Safety
Nature and frequency of adverse events.

Secondary Outcome Measures

Ulcer Improvement (wound bed)
Ulcer Improvement (peri-ulcer)
Healing
Reduction in ulcer area
Healing
Number of subjects healed
Healing
Time to healing
Ulcer pain
Comfort
Ease of use

Full Information

First Posted
December 20, 2011
Last Updated
April 24, 2012
Sponsor
ConvaTec Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01497210
Brief Title
EASH Dressing on Chronic Venous Leg Ulcers
Official Title
A Prospective, Multi-centre, Non-comparative Study to Evaluate the Safety and Preliminary Performance of the EASH Dressing on Chronic Venous Leg Ulcers
Study Type
Interventional

2. Study Status

Record Verification Date
April 2012
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
April 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ConvaTec Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this study is to evaluate the safety and preliminary performance of EASH dressing for 4 weeks followed by AQUACEL® dressing for 4 weeks on venous leg ulcers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leg Ulcer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
EASH
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
EASH dressing
Intervention Description
Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
Primary Outcome Measure Information:
Title
Safety
Description
Nature and frequency of adverse events.
Time Frame
All 8 weeks
Secondary Outcome Measure Information:
Title
Ulcer Improvement (wound bed)
Time Frame
Baseline, week 4 and week 8
Title
Ulcer Improvement (peri-ulcer)
Time Frame
Baseline, week 4 and week 8 or final visit
Title
Healing
Description
Reduction in ulcer area
Time Frame
Weekly for 4 weeks then biweekly for 4 weeks or final visit
Title
Healing
Description
Number of subjects healed
Time Frame
8 weeks or final visit
Title
Healing
Description
Time to healing
Time Frame
8 weeks or final visit
Title
Ulcer pain
Time Frame
Weekly for 4 weeks then biweekly for 4 weeks or final visit
Title
Comfort
Time Frame
Weekly for 4 weeks then biweekly for 4 weeks
Title
Ease of use
Time Frame
Weekly for 4 weeks then biweekly for 4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects over 18 years, willing and able to provide written informed consent. Subjects who have an ankle to brachial pressure index (ABPI) of 0.8 or greater Subjects who have a venous leg ulcer (i.e. CEAP classification of C6 1), with duration less than 24 months and size ranging between 5 cm2-40 cm2. Subjects' leg ulcers will meet at least 3 of the 5 following clinical signs of infection: pain between two dressing changes, peri-ulcer skin erythema/inflammation, oedema, malodour (foul odour), and heavy exudate. Subjects who agree to wear compression therapy daily in combination with the trial dressing. Exclusion Criteria: Subjects with a history of skin sensitivity to any of the components of the study product. Subjects who have had current local or systemic antibiotics in the week prior to inclusion with the exception of wounds that are considered to be clinically infected at baseline. Subjects whose leg ulcers are malignant, or who have had recent deep venous thrombosis or venous surgery within the last 3 months. Subjects who have progressive neoplastic lesion treated by radiotherapy or chemotherapy, or on-going treatment with immunosuppressive agents Subjects exhibiting any other medical condition which, according to the Investigator, justifies the subject's exclusion from the study Subjects who have participated in a clinical study within the past month.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Keith Harding
Organizational Affiliation
Wound Healing Research Unit, Cardiff University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mikomed
City
Lodz
Country
Poland
Facility Name
Cross Medica
City
Warszawa
Country
Poland
Facility Name
Medservice
City
Zabrze
Country
Poland
Facility Name
Wound Healing Research Unit
City
Heath Park
State/Province
Cardiff
ZIP/Postal Code
CF14 4XN
Country
United Kingdom
Facility Name
Axbridge & Wedmore Medical Practice
City
Axbridge
State/Province
Somerset
ZIP/Postal Code
BS26 2BJ
Country
United Kingdom
Facility Name
Arrowe Park Hospital
City
Upton
State/Province
Wirral
ZIP/Postal Code
CH49 5PE
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

EASH Dressing on Chronic Venous Leg Ulcers

We'll reach out to this number within 24 hrs